General | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Comparison | ||||||||||||||||||||||||||||
|
Can you now get a good deal on Lexicon Pharmaceuticals Inc’s shares? | news.google.com • |
Get in on Lexicon Pharmaceuticals Inc’s (LXRX) buy-in window today! | news.google.com • |
Investor’s Delight: Lexicon Pharmaceuticals Inc (LXRX) Closes Strong at 1.70, Up 1.80 | news.google.com • |
LXRX- StockTitan | news.google.com • |
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer | globenewswire.com • |
Lexicon Pharmaceuticals Announces Departure of President and Chief Operating Officer | news.google.com • |
Date | For | Estimate | Reported | Surprise | surprise % |
---|---|---|---|---|---|
2024-11-13 | 2024-09 | -0.16 | N/A | N/A | N/A |
2024-08-01 | 2024-06 | -0.18 | -0.17 | 0.01 | 5.56% |
2024-05-02 | 2024-03 | -0.18 | -0.2 | -0.02 | -11.11% |
2024-03-11 | 2023-12 | -0.23 | -0.2 | 0.03 | 13.04% |
2023-11-08 | 2023-09 | -0.22 | -0.21 | 0.01 | 4.55% |
2023-08-03 | 2023-06 | -0.17 | -0.22 | -0.05 | -29.41% |
Date | Firm | Action | From | To |
---|---|---|---|---|
2023-05-30 | Citigroup | Upgrade | Buy | Buy |
2023-05-29 | Needham | Upgrade | Hold | |
2023-03-06 | Jefferies | Upgrade | Hold | |
2022-11-21 | Citigroup | Upgrade | Buy | Buy |
2022-08-11 | Piper Sandler | Upgrade | Overweight | |
2022-06-30 | Citigroup | Upgrade | Buy |
Date | Name | Relation | Quantity | Description |
---|---|---|---|---|
2024-04-25 | AMOUYAL PHILIPPE | Director | 248.36K | Conversion of Exercise of derivative security |
2024-05-09 | ARTAL INTERNATIONAL S.C.A. | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Conversion of Exercise of derivative security |
2024-04-25 | BARKER SAMUEL L | Director | 87.65K | Conversion of Exercise of derivative security |
2024-02-27 | COATS LONNEL | Chief Executive Officer | 1.10M | Conversion of Exercise of derivative security |
2024-04-25 | DEBBANE RAYMOND | Director | 6.80M | Conversion of Exercise of derivative security |
2024-04-25 | LEFKOWITZ ROBERT J | Director | 48.36K | Conversion of Exercise of derivative security |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Artal Group S.A. | 117.55M | 269.20M | 48.00% |
2023-06-29 | BVF Inc. | 20.00M | 45.79M | 8.16% |
2023-06-29 | FMR, LLC | 8.51M | 19.49M | 3.47% |
2023-06-29 | Vanguard Group Inc | 6.46M | 14.79M | 2.64% |
2023-06-29 | Blackrock Inc. | 6.38M | 14.61M | 2.60% |
2023-06-29 | JP Morgan Chase & Company | 2.93M | 6.71M | 1.20% |
Report Date | Organization | Position | Value | Percentage |
---|---|---|---|---|
2023-06-29 | Vanguard Total Stock Market Index Fund | 3.70M | 8.48M | 1.51% |
2023-08-30 | Fidelity Growth Company Fund | 2.53M | 4.35M | 1.03% |
2023-08-30 | iShares Russell 2000 ETF | 2.15M | 3.69M | 0.88% |
2023-06-29 | JP Morgan Small Cap Value Fund | 1.43M | 3.27M | 0.58% |
2023-06-29 | Vanguard Extended Market Index Fund | 1.42M | 3.25M | 0.58% |
2023-08-30 | Fidelity Select Portfolios - Biotechnology | 1.09M | 1.87M | 0.44% |
Split | Date |
---|---|
1 : 7 | 2015-05-21 |
Feels like they are moving along as planned, and their new management team , to me is an unexpected , huge bonus. No reason really not to be completely confident in this company’s ability to deliver what they’re setting out to in my opinion.
Hummmmm “Ms. DeFrancesco is an accomplished senior executive with nearly 25 years of experience in various investor relations, finance and corporate communications roles”
i’m trying to figure out why they would need someone at this level in this role at this stage?
Buy out talk seems silly here, this feels like it’s setting up for a partnership for at least a year or more, maybe a buy out down the road, but until they can justify 5-10 B valuation I just don’t see it.
I do see them beating estimates on the next call and releasing a sizable catalyst, without big, substantial news it will be hard to keep this above $1 for another 3 months…..
Personally hope there is no buyout, I want to ride the LX9211 wave, any idea how big that market is and how much of a share they will take?? That is where the real money is at. Impefa maybe chump change compared to that.
Also, right around the corner, Sotagliflozin going into registration phase for type 1 D.
$$$
No sales , no SP growth. They would not give a forecast last earning call, so the price dropped like a rock. Being able to answer the question when will you hit $100m in sales would go a long way to setting a better SP
Question for anyone who knows, what multiple of sales do small cap pharma companies like Lexicon sell for?
What annual sales are needed for a 250m market cap?
What was Lexicons sales last 52 wks?
Somewhere in there is probably the answer as to why we are trading at $1, I hate to say.
IMO, no way this does not grow much faster than the market in general over the next year. Everything is lined up, Nov earning call will reset the SP to reflect the real value . Right now, it’s trading like it has no sales, I bet they out perform . ;0)
Guessing once Lexicon gives some additional color to how their launch is going and what we can make of BMS hire addition, this stock price will reset closer to at least where we were at for the second round. Of not it’s going to be a long drag down til the next call on Feb 2024,